Jason Cook - Bluejay Diagnostics Chief Officer
| BJDX Stock | USD 3.75 0.23 6.53% |
Insider
Jason Cook is Chief Officer of Bluejay Diagnostics
| Age | 42 |
| Address | 360 Massachusetts Avenue, Acton, MA, United States, 01720 |
| Phone | 844 327 7078 |
| Web | https://bluejaydx.com |
Jason Cook Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jason Cook against Bluejay Diagnostics stock is an integral part of due diligence when investing in Bluejay Diagnostics. Jason Cook insider activity provides valuable insight into whether Bluejay Diagnostics is net buyers or sellers over its current business cycle. Note, Bluejay Diagnostics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Bluejay Diagnostics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jason Cook over a month ago Disposition of 5324 shares by Jason Cook of Bluejay Diagnostics at 1.09 subject to Rule 16b-3 | ||
Jason Cook over a year ago Bluejay Diagnostics exotic insider transaction detected |
Bluejay Diagnostics Management Efficiency
The company has return on total asset (ROA) of (0.5851) % which means that it has lost $0.5851 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2525) %, meaning that it created substantial loss on money invested by shareholders. Bluejay Diagnostics' management efficiency ratios could be used to measure how well Bluejay Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -1.94 in 2024. Return On Capital Employed is likely to rise to -3.16 in 2024. At this time, Bluejay Diagnostics' Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 30.1 K in 2024, whereas Net Tangible Assets are likely to drop slightly above 6.8 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Danielle Watson | Heart Test Laboratories | 42 | |
| Sandra Eayrs | Nuwellis | N/A | |
| Veronica Cai | Tivic Health Systems | 48 | |
| William MD | Nuwellis | N/A | |
| Laurent Duhoux | Nuwellis | N/A | |
| Marilyn Elson | Nexalin Technology | 71 | |
| Jennifer Ernst | Tivic Health Systems | 56 | |
| Leigh Salvo | IRIDEX | N/A | |
| Sanjay Ahuja | Tivic Health Systems | N/A | |
| Rob Scott | Nuwellis | N/A | |
| David MD | Nexalin Technology | 62 | |
| Patrick Mercer | IRIDEX | 52 | |
| Blake Gurfein | Tivic Health Systems | 40 | |
| Shunichi Kuroda | Bone Biologics Corp | N/A | |
| Ryan Sabia | Tivic Health Systems | 37 | |
| Joel Bradus | Nexalin Technology | N/A | |
| Fuad Ahmad | IRIDEX | 54 | |
Management Performance
| Return On Equity | -1.25 | ||||
| Return On Asset | -0.59 |
Bluejay Diagnostics Leadership Team
Elected by the shareholders, the Bluejay Diagnostics' board of directors comprises two types of representatives: Bluejay Diagnostics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bluejay. The board's role is to monitor Bluejay Diagnostics' management team and ensure that shareholders' interests are well served. Bluejay Diagnostics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bluejay Diagnostics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kenneth CPA, Chief Officer | ||
| Kevin Vance, Chief Officer | ||
| Jason Cook, Chief Officer | ||
| Mark MD, Chief Advisor | ||
| Les DeLuca, Vice Operations | ||
| Eryn Graham, Marketing Manager | ||
| Frances Scally, Principal CFO | ||
| Ryan McSeveney, Corporate Controller | ||
| Mark Feinberg, Chief Advisor | ||
| Indranil Dey, Accounting Financial |
Bluejay Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bluejay Diagnostics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.25 | ||||
| Return On Asset | -0.59 | ||||
| Current Valuation | (3.62 M) | ||||
| Shares Outstanding | 537.68 K | ||||
| Shares Owned By Insiders | 1.14 % | ||||
| Shares Owned By Institutions | 0.95 % | ||||
| Number Of Shares Shorted | 21.06 K | ||||
| Price To Book | 0.26 X | ||||
| Price To Sales | 54.99 X | ||||
| Gross Profit | 48.91 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Bluejay Stock Analysis
When running Bluejay Diagnostics' price analysis, check to measure Bluejay Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bluejay Diagnostics is operating at the current time. Most of Bluejay Diagnostics' value examination focuses on studying past and present price action to predict the probability of Bluejay Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bluejay Diagnostics' price. Additionally, you may evaluate how the addition of Bluejay Diagnostics to your portfolios can decrease your overall portfolio volatility.